9:02am PDT - April 1st, 2022

#Clinicaltrial EAA171/OPTIMUM’s objective is to determine if the addition of ixazomib to lenalidomide improves overall survival for those with previously diagnosed #multiplemyeloma. Learn more here: https://t.co/JqYmEXuDpt #mmsm cc: @myelomaMD @mtmdphd @VincentRK https://t.co/qRDyq6hlPM

0 retweets   2 likes  - ECOG-ACRIN Cancer Research Group (@eaonc)